ArticleNature communications2025
Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From prediction to performance:International journal of pharmaceutics: X · 2026Article
- Rapid Assignment of Chemical Shifts From Crystal Structures in Solid-State NMR.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Proteolysis targeting chimeras (PROTACs) enable degradation of disease-related proteins via E3 ligase recruitment. PROTACs often do not easily crystallize, and they are usually formulated in amorphous forms. Determining the key interactions that stabilize the solid drug forms is of high interest. Here, we determine the complete atomic-level structure of an amorphous Von Hippel-Lindau (VHL)-based SMARCA2 PROTAC (PROTAC 2) using nuclear magnetic resonance (NMR) crystallography. We find that PROTAC 2 is more disordered as compared to previously studied amorphous formulations, and that the three functional units of the molecule have distinct structural types. In contrast to smaller drug molecules, where intermolecular hydrogen bonding interactions were found to be the main stabilization mechanism for the amorphous solid form, for PROTAC 2 we postulate that, in analogy to glassy polymers, the main stabilization mechanism is the entropic contribution introduced by the overall flexibility, especially in the linker region of the molecule. We also note that the most populated conformations found in the amorphous form differ from those of bound PROTAC 2 in the ternary protein complex as determined via X-ray crystallography. Our results provide insight into key structural features that stabilize amorphous formulations, specifically for molecules that can target proteins previously considered undruggable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.